SUO 2015

Washington, DC (UroToday.com) The optimal duration of surveillance for bladder cancer (BC) following radical cystectomy (RC) is unknown.

Washington, DC (UroToday.com) In today’s Adjuvant therapy for localized renal cancer session at the 2015 Society of Urologic Oncology, Dr Uzzo Robert from Fox Chase Cancer center presented the difficulties in finding effective adjuvant therapy for RCC. Dr Uzzo called adjuvant treatment for RCC “the elusive holy grail of surgery” as it will hopefully bridge the gap between incompletely effective surgical therapy and completely effective systemic therapy. 

Washington, DC (UroToday.com): David Cahn and the group from Einstein Healthcare Network and Fox Chase Cancer Center presented on the utilization trends and survival outcomes of patients undergoing radical cystectomy (RC) or bladder preservation therapy (BPT) using National Cancer Database (NCDB).

Washington, DC (UroToday.com) In the SUO meeting poster session Zhiling Zhang and colleagues from the Cleveland Clinic presented their data on acute kidney injury after partial nephrectomy. Acute increase in serum creatinine (sCr) after partial nephrectomy (PN) is primarily due to parenchymal mass reduction or ischemia, however only ischemia can impact subsequent functional recovery. The authors evaluated etiologies of acute kidney injury (AKI) after PN and

Washington, DC (UroToday.com) In the SUO meeting poster session Alexander Kutikov and colleagues from the Fox Chase Cancer Center presented their data on partial nephrectomy resection techniques. Resection methodology during Nephron Sparing Surgery (NSS) is rarely reported. Yet, a relationship between technique and complication rates, preserved parenchymal volume, surgical margins, local recurrence, and oncologic outcomes likely exists. As such, the

Washington, DC (UroToday.com) Radical nephroureterectomy with bladder cuff excision is the gold standard treatment for upper tract urothelial carcinoma (UTUC). For select patients, endoscopic management is another acceptable treatment option. In this study, Kim and colleagues from Washington University in St Louis sought to determine differences in OS and CSS between patients who receive endoscopic versus surgical management of UTUC. Using SEER-

Washington, DC (UroToday.com) In today’s prostate cancer session at the 2015 Society of Urologic Oncology, Dr. Felix Feng from the University of Michigan presented his data og PARP inhibitors in prostate cancer treatment. It is known that 23% of CRPC harbor DNA repair alterations. Single DNA strand damage is repaired by the PARP protein. By inhibiting the protein the damage is not repaired but progresses to double strand damage. Since many cancers harbor DNA repair alterations (e.g. BRCA,